What is RAMPART?

RAMPART (Renal Adjuvant MultiPle Arm Randomised Trial) is an international investigator-led phase III multi arm multi stage multi-centre randomised controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.

Why are we running this study?

At the present time no adjuvant therapy has been proven to be effective for RCC patients. The most recent generation of adjuvant trials in RCC tested tyrosine kinase inhibitors (TKIs) targeting the vascular endothelial growth factor receptor. Unfortunately, despite showing efficacy in advanced RCC, those results have not successfully translated into the adjuvant setting.

The current global standard of care after nephrectomy for localised RCC therefore remains active monitoring (i.e., observation by clinical and radiological means). We know that 30-40% of patients with initially localised RCC develop metastatic disease following nephrectomy. The need for adjuvant therapy is most marked in the high‑risk population where outcomes are predictably poor. Intermediate risk patients also have a substantial risk of relapse and will be recruited in the early years of the trial (up to 3 years or when intermediate risk patients contribute 25% of the total accrual target).

What are the trial interventions?

The drugs being tested are immunotherapy drugs also referred to as immune checkpoint inhibitors. They work by unleashing or enhancing patient’s pre-existing anticancer immune responses. Durvalumab, an anti-PDL1 drug, is currently being tested in a number of different types of cancer; both as a single therapy and in combination. It has recently be licensed for use in the treatment of non-small cell lung cancer. Tremelimumab, an anti-CTLA4 drug, has been shown to be effective in treating various different types of cancer, especially when used in combination with other cancer treatments.

What are the study aims?

The RAMPART platform trial has been designed to evaluate multiple treatments simultaneously, whilst adapting to a changing landscape as data on different agents and combinations of agents emerges.

The aims for the initial research comparisons are as follows:


Does treatment with either durvalumab alone or a combination of durvalumab and tremelimumab increase Disease Free Survival (DFS) compared with active monitoring (Arm B vs Arm A, and Arms C vs Arm A respectively)?


Does treatment with either durvalumab alone or a combination of durvalumab and tremelimumab increase Overall Survival (OS) compared with active monitoring in patients classified as Leibovich high risk (Arm B vs Arm A, and Arms C vs Arm A respectively)?
Who can take part?

RAMPART is now closed to recruitment and is not enrolling any new patients to the trial.


  • Histologically proven RCC (all cell types of RCC are eligible, except for pure oncocytoma, collecting duct, medullary and transitional cell cancer [TCC]); no evidence of residual macroscopic disease on post-operative CT scan after resection of RCC. Patients with treated bilateral synchronous RCCs are eligible.
  • At the start of recruitment patients with Leibovich score 3-11 will be eligible for randomisation. MRC CTU at UCL will monitor accrual and stop recruiting intermediate risk patients (Leibovich Score 3-5) after three years or when intermediate risk patients contribute 25% of the total accrual target, whichever is earlier. Recruitment of patients with Leibovich Score 6‑11 will continue until the accrual target is reached.
  • Patients should have had surgery at least 28 days but no more than 91 days prior to their randomisation date.
  • Post-operative scans should be performed within 28 days prior to randomisation.
  • Patients with microscopically positive resection margins after radical nephrectomy at the nephrectomy bed, renal vein or inferior vena cava are eligible provided the post-operative CT scan shows no evidence of residual macroscopic disease.
  • WHO Performance Status 0 or 1.
  • Patient has archival FFPE pathology tissue available, and agrees to provide at least one sample (FFPE tumour block from nephrectomy, or a minimum of 10 unstained slides), as well as a baseline EDTA blood sample for future translational research (this is separate to providing consent for TransRAMPART).
  • Adequate normal organ and marrow function:
    • Haemoglobin ≥9.0g/dL (transfusions will be allowed within 2 weeks prior to randomisation in order to achieve the entry criteria).
    • Absolute neutrophil count (ANC) ≥1.5 x 109/L (≥1500 per mm3).
    • Platelet count ≥100 x 109 (≥100,000 per mm3).
    • Bilirubin ≤1.5 x ULN (This will not apply to subjects with confirmed Gilbert’s syndrome (i.e., persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of haemolysis or hepatic pathology), who will be allowed only in consultation with their physician).
    • AST/ALT ≤2.5 x ULN.
    • Calculated Creatinine Clearance level >40mL/min by Cockcroft Gault formula (using actual body weight).
  • 12-lead ECG on which QTcF must be <450 ms. In case of clinically significant ECG abnormalities, including a QTcF value ≥450 ms, two additional 12-lead ECGs should be obtained over a brief period (e.g., 30 minutes) to confirm the finding. Patients are only eligible if a QTcF of <450ms is confirmed
  • Subjects must be ≥18 years of age.
  • Written informed consent obtained from the patient.
  • Both men and women enrolled in this trial must be in agreement with trial policy on contraception during the treatment phase of the study and 6 months afterwards. Egg donation, sperm donation and breastfeeding must be avoided.
  • Evidence of post-menopausal status or negative serum HCG pregnancy test for female pre‑menopausal patients. Women will be considered post-menopausal if they have been amenorrhoeic for 12 months without an alternative medical cause. The following age‑specific requirements apply:
    • Women <50 years of age will be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinising hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilisation (bilateral oophorectomy or hysterectomy).
    • Women ≥50 years of age will be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy‑induced menopause with last menses >1 year ago, or underwent surgical sterilisation (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).
  • Previous diagnosis of RCC.
  • Metastatic or macroscopic residual disease.
  • Patients with positive resection margins after partial nephrectomy
  • Patients with a single pulmonary nodule ≥5mm diameter are not eligible unless the nodule has had a definite benign diagnosis. Patients with multiple small, less than 5 mm nodules may be eligible if nodules have been shown to be radiologically stable for at least 8 weeks.
  • Prior anticancer treatment (other than nephrectomy) for RCC.
  • Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria.
    • Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician.
    • Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or tremelimumab may be included only after consultation with the Study Physician.
  • History of another primary malignancy except for:
    • Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IP and of low potential risk for recurrence.
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
    • Adequately treated carcinoma in situ without evidence of disease.
  • History of leptomeningeal carcinomatosis.
  • Concurrent enrolment in another clinical study, unless it is an observational (non‑interventional) clinical study or during the follow‑up period of an interventional study.
  • Major surgical procedure (as defined by the Investigator) within 28 days prior to the start of treatment. Local surgery of isolated lesions for palliative intent is acceptable.
  • Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid.
  • Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:
    • Patients with vitiligo or alopecia.
    • Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement.
    • Any chronic skin condition that does not require systemic therapy.
    • Patients without active disease in the last 5 years may be included but only after consultation with the RAMPART team.
    • Patients with coeliac disease controlled by diet alone.
  • A history of immunodeficiency syndrome. Please consult the RAMPART team on an individual basis if there is any uncertainty.
  • History of allogeneic organ transplant.
  • Uncontrolled intercurrent illness including, but not limited to:
    • Ongoing or active infection.
    • Symptomatic congestive heart failure.
    • Uncontrolled hypertension.
    • Unstable angina pectoris.
    • Uncontrolled cardiac arrhythmia.
    • Active peptic ulcer disease or gastritis.
    • Active bleeding diatheses.
    • Psychiatric illness or social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent.
  • Active infection including.
    • Tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice)
    • Hepatitis B (known positive HBV surface antigen (HBsAg) result). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti‑HBc] and absence of HBsAg) are eligible. 
    • Hepatitis C
    • Human immunodeficiency virus (positive HIV 1/2 antibodies).

Note: Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.

  • Receipt of live attenuated vaccine within 30 days prior to the start of treatment. Note: Patients, if enrolled, should not receive live vaccine while receiving investigational medicinal product and up to 30 days after the last dose of investigational medicinal product.
  • Pregnant or breastfeeding patients.
  • Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results.
  • Known allergy or hypersensitivity to durvalumab or tremelimumab, or any of their excipients.
  • Previous investigational medicinal product assignment in the present study.
Where is the study being conducted?

The RAMPART trial closed to recruitment on 30th June 2023.


More Information

For full details of the RAMPART study, please refer to the RAMPART Protocol